OverviewSuggest Edit

Insulet Corporation, a medical device company, develops, manufactures, and sells insulin delivery systems for people with insulin-dependent diabetes in the United States and internationally. The Company offers Omnipod Insulin Management System (Omnipod System), which consists of the OmniPod, an easy-to-use continuous insulin delivery system and Personal Diabetes Manager, a handheld wireless device. It also customizes the Omnipod System technology platform for the delivery of subcutaneous drugs across various therapeutic areas. Insulet Corporation sells and markets its Omnipod System through a combination of direct sales representatives and independent distributors.

HQActon, MA, US
Overall CultureD+

Latest Updates

Employees (est.) (Dec 2019)1,350(+16%)
Job Openings257
Revenue (FY, 2020)$904.4 M(+23%)
Share Price (Jul 2021)$278.6(+2%)
Cybersecurity ratingBMore

Key People/Management at Insulet

Shacey Petrovic

Shacey Petrovic

Director, President and Chief Executive Officer
Sally W. Crawford

Sally W. Crawford

Charles Alpuche

Charles Alpuche

Executive Vice President and Chief Operating Officer
John Fallon

John Fallon

Jim Hollingshead

Jim Hollingshead

Bret Christensen

Bret Christensen

Executive Vice President and Chief Commercial Officer
Show more

Insulet Office Locations

Insulet has offices in Acton, Billerica, Charlotte, Chicago and in 12 other locations
Acton, MA, US (HQ)
100 Nagog Park
Billerica, MA, US
600 Technology Park Dr #200
Charlotte, NC, US
Charlotte, NC, USA
Chicago, IL, US
Chicago, IL, USA
Columbus, OH, US
Columbus, OH, USA
Denver, CO, US
Denver, CO, USA
Show all (16)

Insulet Financials and Metrics

Insulet Revenue

Embed Graph
View revenue for all periods
Insulet's revenue was reported to be $904.4 m in FY, 2020

Revenue (Q1, 2021)


Gross profit (Q1, 2021)


Gross profit margin (Q1, 2021), %


EBIT (Q1, 2021)


Market capitalization (1-Jul-2021)


Closing stock price (1-Jul-2021)


Cash (31-Mar-2021)



Insulet's current market capitalization is $18.4 b.
USDFY, 2011FY, 2012FY, 2013FY, 2014FY, 2015FY, 2016FY, 2017FY, 2018FY, 2019FY, 2020

Net Income


Depreciation and Amortization




Accounts Payable

USDQ2, 2011

Financial Leverage

2.4 x
Show all financial metrics

Insulet Operating Metrics

FY, 2016

Patents Issued


Patents Pending

Show all operating metrics

Insulet Revenue Breakdown

Embed Graph

Insulet revenue breakdown by business segment: 62.6% from U.S. Omnipod, 19.6% from International Omnipod and 17.8% from Drug Delivery

Insulet Cybersecurity Score

Cybersecurity ratingPremium dataset



SecurityScorecard logo

Insulet Environment, Social & Governance (ESG) Ratings

CSRHub ESG ratingPremium dataset


out of 100

CSRHub logo

Insulet Online and Social Media Presence

Embed Graph

Insulet Company Culture

  • Overall Culture



  • CEO Rating



  • Compensation



  • Diversity



Learn more on Comparably

Insulet News and Updates

Global Insulin Pens, Syringes, Pumps and Injectors Market 2021-2030 with Novo Nordisk A/S, Eli Lilly and Co, Medtronic, Abbott, and Insulet Dominating

Dublin, May 24, 2021 (GLOBE NEWSWIRE) -- The "Insulin Pens, Syringes, Pumps and Injectors Global Market Report 2021: COVID-19 Implications and Growth to 2030" report has been added to ResearchAndMarkets.com's offering. Major players in the insulin pens, syringes, pumps and injectors market are Nov…

Infusion Pumps Market Growth & Revenue 2020 to 2025 | Smith Medical, Moog, ICU Medical, Insulet

Volumetric pumps are driving the market for infusion pumps over the forecast period, in the type segment Posted via Industry Today. Follow us on Twitter @IndustryToday

Abbott and Insulet Partner to Integrate Next-Generation Glucose Sensing and Automated Insulin Delivery Technologies for Seamless Diabetes Care

ABBOTT PARK, Ill. and ACTON, Mass., Feb. 19, 2020 /PRNewswire/ -- Abbott (NYSE: ABT) and Insulet Corporation (NASDAQ: PODD), the global leader in tubeless insulin pump technology with its Omnipod® Insulin Management System (Omnipod System), announced today they are partnering to integrate...

lobal Artificial Pancreas Systems Market Report 2019 Top Key Players- Medtronic, Johnson and Johnson, Dexcom, Insulet, Tandem Diabetes Care and more...

A new market study, titled “Global Artificial Pancreas Systems Market Report 2019 - Market Size, Share, Price, Trend and Forecast”, has been featured on WiseGuyReports. Posted via Industry Today. Follow us on Twitter @IndustryToday

Why Is Insulet Stock Up More Than 15% Over The Last Month?

Insulet (NASDAQ: PODD), a company best known for selling the Omnipod continuous insulin delivery system that caters to people with diabetes, has seen its stock price rally by close to 17% over the last month. There have been multiple factors driving the rally. Firstly, the company posted stronger...

Medication Telemanagement Devices Market 2018 Global Analysis By Key Players – Abiogenix, Adherium, IA Collaborative, Insulet, MedFolio

Wiseguyreports.Com adds “Medication Telemanagement Devices Market –Market Demand, Growth, Opportunities, Analysis of Top Key Players and Forecast to 2025” To Its Research Database. Posted via Industry Today. Follow us on Twitter @IndustryToday
Show more

Insulet Frequently Asked Questions

  • When was Insulet founded?

    Insulet was founded in 2000.

  • Who are Insulet key executives?

    Insulet's key executives are Shacey Petrovic, Sally W. Crawford and Charles Alpuche.

  • How many employees does Insulet have?

    Insulet has 1,350 employees.

  • What is Insulet revenue?

    Latest Insulet annual revenue is $904.4 m.

  • What is Insulet revenue per employee?

    Latest Insulet revenue per employee is $669.9 k.

  • Who are Insulet competitors?

    Competitors of Insulet include Tandem Diabetes Care, Genteel and POPS! Diabetes Care.

  • Where is Insulet headquarters?

    Insulet headquarters is located at 100 Nagog Park, Acton.

  • Where are Insulet offices?

    Insulet has offices in Acton, Billerica, Charlotte, Chicago and in 12 other locations.

  • How many offices does Insulet have?

    Insulet has 16 offices.